Zanzalintinib in Unresectable and Progressive MPGGs

NCT07714551 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Pheochromocytoma
Paraganglioma

Interventions

DRUG: Zanzalintinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]